8-K: Calidi Biotherapeutics Terminates Equity Purchase Agreement After Successful Capital Raises

Calidi Biotherapeutics terminated its Standby Equity Purchase Agreement after raising $18.85 million through public offerings, warrant exercises, and its ATM program, strengthening its cash position.

Summary

• Calidi Biotherapeutics has terminated its Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors, effective January 23, 2025.
• The SEPA, which was established in December 2023, allowed Calidi the option to sell up to $25 million of common stock, but this option was never exercised.
• The termination of the SEPA was mutually agreed upon, with no outstanding borrowings, advance notices, or shares to be issued, and no fees due.
• In the fourth quarter of 2024, Calidi raised $9.5 million through two public offerings, $2.0 million from warrant exercises, and $3.1 million from its at-the-market (ATM) program.
• In January 2025, Calidi raised an additional $4.25 million through another public offering.
• These capital raises have significantly improved Calidi's cash position, allowing them to meet capital requirements without relying on the SEPA.
• Calidi's cash balance at December 31, 2024, was approximately $9.6 million.
• The company is focused on its clinical and operational goals, including the presentation of its systemic platform at the AACR Annual Meeting in April 2025 and the start of a Phase 1b/2 trial for CLD-101 in the first quarter of 2025.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful capital raises and the termination of the SEPA, which removes a potential risk. The company's focus on clinical milestones and the development of innovative therapies also contributes to the positive outlook. However, the preliminary nature of the financial data and the inherent risks in clinical trials prevent a perfect score.

Positives

• The termination of the SEPA removes a potential overhang on the stock.
• Calidi has successfully raised a total of $18.85 million through various financing activities.
• The company's strengthened cash position allows it to focus on clinical and operational goals.
• Calidi has achieved key milestones, including the acceptance of its systemic platform for presentation at the AACR Annual Meeting and IND clearance for a Phase 1b/2 trial.
• The company is well-positioned to meet its capital needs without relying on the SEPA framework.

Negatives

• The financial data presented is preliminary and unaudited, subject to further review and potential adjustments.
• Actual financial results may differ materially from the preliminary estimates provided.

Risks

• The company's actual financial results may differ materially from the preliminary estimates due to the completion of financial closing procedures and other developments.
• There is a risk that Calidi may not be able to raise sufficient capital to support its clinical trials.
• Early results of clinical trials may not predict final results, and clinical outcomes may change following further review.
• There is a risk that Calidi may not receive FDA approval for its therapeutic candidates.

Future Outlook

Calidi is focused on advancing its clinical programs, including the presentation of its systemic platform at the AACR Annual Meeting in April 2025 and the start of a Phase 1b/2 trial for CLD-101 in the first quarter of 2025. The company believes it is well-positioned to meet its capital needs without relying on the SEPA framework.

Management Comments

• Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics, stated that the termination of the SEPA marks an important milestone in their financing strategy.
• He also mentioned that the company is well-positioned to focus on its clinical and operational goals and remove a potential overhang in their stock.
• Management believes the recent capital raises have strengthened the company's cash position.

Industry Context

The termination of the SEPA and the successful capital raises indicate a shift in Calidi's financing strategy, moving away from potentially dilutive agreements towards more traditional funding methods. This is a positive sign for investors as it reduces the risk of future stock dilution. The focus on clinical milestones and the development of innovative virotherapy platforms aligns with the broader trend in the biotechnology industry towards targeted and personalized cancer treatments.

Comparison to Industry Standards

• Calidi's decision to terminate the SEPA is similar to other biotech companies that seek to reduce reliance on potentially dilutive financing methods as they progress through clinical trials.
• The $18.85 million raised through public offerings, warrant exercises, and the ATM program is a significant amount for a clinical-stage biotech company, comparable to other companies at a similar stage of development.
• The focus on virotherapy platforms is in line with the industry's move towards innovative cancer treatments, with companies like Amgen and Oncolytics Biotech also exploring oncolytic viruses.
• The planned Phase 1b/2 trial for CLD-101 is a typical step for a company developing a new therapeutic candidate, similar to other companies in the immuno-oncology space.

Stakeholder Impact

• Shareholders will likely view the termination of the SEPA and the successful capital raises positively.
• Employees may benefit from the company's improved financial stability and focus on clinical development.
• Customers (patients) may benefit from the advancement of Calidi's innovative therapies.
• Suppliers and creditors may have increased confidence in the company's ability to meet its obligations.

Next Steps

• Calidi will present its systemic platform at the AACR Annual Meeting in April 2025.
• The company plans to start enrollment in a Phase 1b/2 trial for CLD-101 in the first quarter of 2025.
• The company will continue to advance its clinical programs and develop its virotherapy platforms.

Key Dates

Keywords

Calidi Biotherapeutics, Standby Equity Purchase Agreement, SEPA, capital raise, public offering, warrant exercises, ATM program, cash balance, virotherapy, clinical trials, oncology, CLD-101